Senza5 CART5

Senza5 CART5 (VIPER-101) is an autologous CAR-T cell therapy (gene-edited, dual-population) from Vittoria Biotherapeutics, with University of Pennsylvania as partner. A gene-edited autologous CD5-directed CAR-T product made of two engineered cell populations, CD5-knockout cells and CD5-knockout CART5 cells. Its furthest stage is phase 1, for T-cell non-Hodgkin lymphoma. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 NCT06420089 recruiting; long-term follow-up study NCT07683897 not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.